Phaseline

Companies › ProJenX

ProJenX: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Neurology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
prosetin–Phase 1Amyotrophic Lateral Sclerosis–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05279755prosetinPhase 1Amyotrophic Lateral SclerosisNeurologyJun 2026

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.